Maritza was diagnosed with factor X deficiency as a young adult but didn’t receive treatment until she had a miscarriage with her first child. Now a mother of 3 children, she hopes her story of determination, seeking answers, and getting involved will inspire others with factor X deficiency to live their best life.
Although she was anemic as a child, Maritza did not know she had factor X deficiency until she was hospitalized at age 21 for severe bleeding after dental surgery. Since she lived in the Dominican Republic and could not obtain fresh frozen plasma (FFP), Maritza was given birth control pills to help control her heavy menstrual bleeding.
After moving to the United States with her husband, Maritza became pregnant with her first child but suffered a miscarriage. Testing confirmed she had factor X deficiency. Sadly, she was told she could not have children. Seeking answers, Maritza found a high-risk pregnancy specialist who treated her with FFP. With specialty care she was able to have three healthy children. But she also had health issues, including a severe allergic reaction to FFP. No longer able to receive treatment, she became fearful of injury and began limiting her activity.
Maritza’s life changed when she found out about COAGADEX from her doctor. “For 23 years I had nothing. Now I do have something—and it’s made just for me,” she said. With a new confidence gained from the availability of COAGADEX, she began to get more involved in the bleeding disorders community and even attended the National Hemophilia Foundation’s annual meeting in Chicago in 2017. There she gained new friendships and information to discuss with her doctor.
She is thankful she joined NHF to learn more and encourages other factor X families to do the same.
Indications and Usage for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:
- Routine prophylaxis to reduce the frequency of bleeding episodes
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding in patients with mild and moderate hereditary factor X deficiency
Limitation of Use
Perioperative management of bleeding in major surgery in patients with severe hereditary factor X deficiency has not been studied.
Contraindication for COAGADEX
COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.
Important Safety Information for COAGADEX
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.
The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.